MSB 2.70% 95.0¢ mesoblast limited

What one commentator in Alpha said: "This is the kind of report...

  1. 30,340 Posts.
    lightbulb Created with Sketch. 1837
    What one commentator in Alpha said:

    "This is the kind of report you would expect from someone who is shorting the stock and is about to lose their pants."

    What baffles me is why the Japanese regulator would even bother to approve a treatment aGVHD that is supposedly ineffective. Plus the FDA followed suit.

    Approval is conditional on efficacy being proven. Who writes this stuff? It's not even a serious attempt at fiction.

    There is such an aggressive take on MSB which is breathtaking in audacity and inaccuracies, worse than Macbank (and that's saying something!).

    They say clinical trial data has been data-mined, but they seem to take no account of the fact that in the safety trials and stage 2, different doses were given to work out efficacy. If that's data mining, they need to be introduced to fast tracking...which is what the FDA did with aGVHD and has agreed to look at halfway through the stage 3 clinical trials of spinal disk and congestive heart failure therapies. None of this seems to have filtered their cranial area. It reads like an angry rant.

    The main thing is the issue is underwritten and has Morgan Stanley & ors involved. More savvy investors will take a closer look at this and not be swayed by such a weird 'report'. It doesn't even bother to try to be even handed.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
95.0¢
Change
0.025(2.70%)
Mkt cap ! $1.084B
Open High Low Value Volume
94.0¢ 96.8¢ 93.5¢ $4.207M 4.417M

Buyers (Bids)

No. Vol. Price($)
3 42268 94.0¢
 

Sellers (Offers)

Price($) Vol. No.
95.0¢ 48002 3
View Market Depth
Last trade - 16.10pm 09/08/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.